Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Muhamed-Kheir Taha, Federico Martinon-Torres, Ralph Köllges, Paolo Bonanni, Marco Aurelio Palazzi Safadi, Robert Booy, Vinny Smith, Stéphanie Garcia, Rafik Bekkat-Berkani & Véronique Abitbol. (2022) Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease. Expert Review of Vaccines 21:5, pages 659-674.
Read now
Read now
Woo-Yun Sohn, Halima Tahrat, Patricia Novy & Rafik Bekkat-Berkani. (2022) Real-world implementation of 4-component meningococcal serogroup B vaccine (4CMenB): implications for clinical practices. Expert Review of Vaccines 21:3, pages 325-335.
Read now
Read now
Rouba Shaker, Danielle Fayad & Ghassan Dbaibo. (2018) Challenges and opportunities for meningococcal vaccination in the developing world. Human Vaccines & Immunotherapeutics 14:5, pages 1084-1097.
Read now
Read now
N. Y. Wang & A. J. Pollard. (2018) The next chapter for group B meningococcal vaccines. Critical Reviews in Microbiology 44:1, pages 95-111.
Read now
Read now
Articles from other publishers (19)
Katharina Schley, Jack C. Kowalik, Shannon M. Sullivan, Andrew Vyse, Carole Czudek, Eszter Tichy & Jamie Findlow. (2023) Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK: Does the Adolescent MenACWY Programme Provide Sufficient Protection?. Vaccines 11:5, pages 940.
Crossref
Crossref
Kris Doggen, Albert Jan van Hoek & Jeroen Luyten. (2023) Accounting for Adverse Events Following Immunization in Economic Evaluation: Systematic Review of Economic Evaluations of Pediatric Vaccines Against Pneumococcus, Rotavirus, Human Papillomavirus, Meningococcus and Measles-Mumps-Rubella-Varicella. PharmacoEconomics 41:5, pages 481-497.
Crossref
Crossref
Jing Shen, Najida Begum, Yara Ruiz-Garcia, Federico Martinon-Torres, Rafik Bekkat-Berkani & Kinga Meszaros. (2022) Range of invasive meningococcal disease sequelae and health economic application – a systematic and clinical review. BMC Public Health 22:1.
Crossref
Crossref
Catherine Weil-Olivier, Muhamed-Kheir Taha, Corinne Emery, Stéphane Bouée, Ekkehard Beck, Emmanuel Aris, Véronique Loncle-Provot, Gaëlle Nachbaur & Céline Pribil. (2021) Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database. Infectious Diseases and Therapy 10:3, pages 1607-1623.
Crossref
Crossref
Ifechukwu B. Nwogu, Matthew Jones & Tessa Langley. (2021) Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review. Vaccine 39:16, pages 2201-2213.
Crossref
Crossref
Lieven Annemans, Philippe Beutels, David E. Bloom, Wilfried De Backer, Olivier Ethgen, Jeroen Luyten, Philippe Van Wilder, Lander Willem & Steven Simoens. (2021) Economic Evaluation of Vaccines: Belgian Reflections on the Need for a Broader Perspective. Value in Health 24:1, pages 105-111.
Crossref
Crossref
Ekkehard Beck, Johan Klint, Mohamed Neine, Stephanie Garcia & Kinga Meszaros. (2021) Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease. Value in Health 24:1, pages 91-104.
Crossref
Crossref
Sara Boccalini, Beatrice Zanella, Paolo Landa, Daniela Amicizia, Angela Bechini, Maddalena Innocenti, Mariasilvia Iovine, Elvina Lecini, Francesca Marchini, Diana Paolini, Gino Sartor, Francesca Zangrillo, Piero Luigi Lai, Paolo Bonanni & Donatella Panatto. (2020) Why the Anti-Meningococcal B Vaccination during Adolescence Should Be Implemented in Italy: An Overview of Available Evidence. Microorganisms 8:11, pages 1681.
Crossref
Crossref
Andrew Stawasz, Liping Huang, Paige Kirby & David Bloom. (2020) Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits. Frontiers in Public Health 8.
Crossref
Crossref
Rafael Ruiz-Montero, David Epstein, Bernardo Guzmán Herrador & Jaime Espín Balbino. (2020) Evaluación económica de la inclusión en el calendario vacunal de 4CMenB (Bexsero®) en España. Gaceta Sanitaria 34:4, pages 318-325.
Crossref
Crossref
Sara Boccalini, Angela Bechini, Cecilia Maria Alimenti, Paolo Bonanni, Luisa Galli & Elena Chiappini. (2020) Assessment of the Clinical and Economic Impact of Different Immunization Protocols of Measles, Mumps, Rubella and Varicella in Internationally Adopted Children. Vaccines 8:1, pages 60.
Crossref
Crossref
Ole Marten, Florian Koerber, David Bloom, Monika Bullinger, Corinne Buysse, Hannah Christensen, Philippe De Wals, Christian Dohna-Schwake, Philipp Henneke, Markus Kirchner, Markus Knuf, Burkhard Lawrenz, Andrea L. Monteiro, Joseph Patrick Sevilla, Nicolas Van de Velde, Robert Welte, Claire Wright & Wolfgang Greiner. (2019) A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease. Health and Quality of Life Outcomes 17:1.
Crossref
Crossref
Marcelle Moura Silveira, Alan J.A. McBride & Caroline L. Trotter. (2019) Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme. Vaccine 37:45, pages 6783-6786.
Crossref
Crossref
Bing Wang, Hossein Haji Ali Afzali, Lynne Giles & Helen Marshall. (2019) Lifetime costs of invasive meningococcal disease: A Markov model approach. Vaccine 37:46, pages 6885-6893.
Crossref
Crossref
Stefan Scholz, Florian Koerber, Kinga Meszaros, Rosa Maya Fassbender, Bernhard Ultsch, Robert R. Welte & Wolfgang Greiner. (2019) The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine 37:12, pages 1692-1701.
Crossref
Crossref
Bing Wang, Renee Santoreneos, Hossein Afzali, Lynne Giles & Helen Marshall. (2018) Costs of Invasive Meningococcal Disease: A Global Systematic Review. PharmacoEconomics 36:10, pages 1201-1222.
Crossref
Crossref
Paul Balmer & Laura J. York. (2018) Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control. Therapeutic Advances in Vaccines and Immunotherapy 6:3, pages 49-60.
Crossref
Crossref
Miguel Delgado Rodríguez & Ángela Domínguez García. (2018) Pros y contras de la vacunación frente a la enfermedad por meningococo B. Medicina Clínica 150:3, pages 109-113.
Crossref
Crossref
Miguel Delgado Rodríguez & Ángela Domínguez García. (2018) Pros and cons of vaccination against disease caused by serogroup B meningococcal disease. Medicina Clínica (English Edition) 150:3, pages 109-113.
Crossref
Crossref